Immunic Earnings Call Transcripts
Fiscal Year 2026
-
2026 is set to be pivotal with phase III RMS data and NDA submission preparations. Vidofludimus calcium offers a unique safety and neuroprotective profile, targeting both relapsing and progressive MS, with strong clinical data and significant commercial potential.
-
Vidofludimus Calcium offers a unique dual mechanism for MS, showing strong efficacy and safety in phase II trials. Phase III studies in relapsing MS are fully enrolled and expected to read out by year-end, while a pivotal PPMS trial is set to launch, targeting a multi-billion-dollar market opportunity.
Fiscal Year 2025
-
Upcoming Phase 3 data in relapsing MS and strong Phase 2 results in progressive MS highlight a pivotal year ahead. The therapy's unique neuroprotective mechanism and favorable safety profile position it to compete strongly in the oral MS market, with significant financial and partnership flexibility.
-
Vidofludimus calcium, a dual-mechanism oral therapy, shows robust efficacy and safety in both relapsing and progressive MS, with significant reductions in disability and strong biomarker support. Phase III trials are fully enrolled, with top-line data expected in late 2026.
-
New phase 2 data show vidofludimus calcium reduces disability progression in progressive MS, with strong efficacy even in patients without active inflammation. ENSURE phase 3 studies in relapsing MS are fully enrolled, and IMU-856 shows promise in celiac disease and weight management.
-
The phase II CALLIPER trial showed vidofludimus calcium reduced disability progression in progressive MS, with a 20% overall and 30% reduction in PPMS, and demonstrated neuroprotective effects even in non-inflammatory patients. The drug maintained a strong safety profile and could address a major unmet need in MS.
-
Upcoming phase 2 and 3 readouts for vidofludimus calcium in MS are set to address major unmet needs, with strong biomarker and safety data supporting its potential. Strategic partnerships and robust financing position the asset for significant market impact.
-
Vidofludimus calcium is advancing as a dual-mechanism therapy for MS, with key Phase II and III trials targeting both neuroprotection and anti-inflammation. Its unique profile and favorable safety position it strongly in a large, underserved market, with significant partnership interest and blockbuster potential.
Fiscal Year 2024
-
Upcoming data from the CALLIPER phase 2 study in April 2025 and ENSURE-1/2 phase 3 studies in 2026 are set to address major unmet needs in progressive and relapsing MS. The drug's unique dual mechanism, strong safety, and robust patent protection could position it as a best-in-class therapy.
-
Management strengthened and clinical pipeline advanced, with vidofludimus calcium progressing in both relapsing and progressive MS. Q3 net loss widened to $24.4M, cash runway extends into Q3 2025, and key trial readouts are expected in 2025 and 2026.
-
The conference highlighted progress in oral therapies for MS, with vidofludimus calcium showing strong efficacy and neuroprotection via dual mechanisms. Key trials target unmet needs in progressive MS, and a promising GI pipeline asset demonstrated clinical proof of concept in celiac disease.
-
Q2 2024 saw strong clinical and operational progress, with pivotal MS trials advancing and key data readouts expected in the next year. Cash reserves of $79.7M extend runway into Q3 2025, while management and board additions strengthen commercialization prospects.